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Abstract: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are incurable, devastating
neurodegenerative disorders characterized by the formation and spreading of protein aggregates
throughout the brain. Although the exact spreading mechanism is not completely understood,
extracellular vesicles (EVs) have been proposed as potential contributors. Indeed, EVs have emerged
as potential carriers of disease-associated proteins and are therefore thought to play an important
role in disease progression, although some beneficial functions have also been attributed to them.
EVs can be isolated from a variety of sources, including biofluids, and the analysis of their content can
provide a snapshot of ongoing pathological changes in the brain. This underlines their potential as
biomarker candidates which is of specific relevance in AD and PD where symptoms only arise after
considerable and irreversible neuronal damage has already occurred. In this review, we discuss the
known beneficial and detrimental functions of EVs in AD and PD and we highlight their promising
potential to be used as biomarkers in both diseases.
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1. Introduction
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common
neurodegenerative disorders characterized by the misfolding, aggregation and widespread
accumulation of natively unfolded proteins [1,2]. In the case of AD, amyloid beta (Aβ) deposits
into extracellular Aβ plaques, whereas the hyperphosphorylation of the protein Tau leads to the
formation of neurofibrillary tangles inside neurons [3]. These lesions lead to the loss of synapses
and neurodegeneration which result in the symptoms associated with AD [4]. In PD, the protein
alpha-synuclein (α-syn) aggregates into intraneuronal Lewy bodies and Lewy neurites [5]. The second
neuropathological hallmark of PD is the loss of dopaminergic neurons in the substantia nigra pars
compacta, leading to functional impairment of the nigrostriatal pathway and the occurrence of the
cardinal motor symptoms [6]. Interestingly, the Tau and α-syn pathology spreads throughout the
brain in a predictable, characteristic pattern [7,8]. This is thought to be the result of their cell-to-cell
transmission in a prion-like fashion, whereby the pathologic aggregates from the donor neuron induce
the misfolding of their endogenous counterparts in the acceptor neuron [9]. In contrast to Tau pathology,
amyloid plaques display a less predictable spreading pattern whereby their presence does not correlate
well with cognitive decline either [10,11]. Consequently, the research focus has shifted towards soluble
Aβ oligomers (AβOs) as being the main neurotoxic Aβ conformation capable of inducing synaptic
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dysfunction [11,12]. These oligomers also appear to be the most potent conformation related to the
proposed hypothesis of prion-like spreading of Aβ pathology [13]. Although the exact spreading
mechanism of these disease-related proteins is not completely understood, extracellular vesicles (EVs)
have been proposed as one of the contributors [14].
EVs are nanosized membrane vesicles that can be classified as exosomes or microvesicles based
on their mode of biogenesis. They are important mediators of intercellular communication due to their
capacity to transfer proteins, lipids and genetic material to both adjacent and distant cells whereby
they influence various physiological and pathological functions [15]. Although a major part of the
research cited in this review utilizes specific nomenclature to describe EV subtypes, we decided to
consistently use the general term “EVs”. The rationale behind this is that it is currently still very
difficult to discriminate between EV subtypes due to the lack of subtype-specific markers [16]. In this
review, we first discuss the role of EVs in AD. Hereby, we elaborate on how the proteolytic cleavage of
the amyloid precursor protein (APP) can lead to the release of Aβ in association with EVs whereafter
we review the known beneficial and detrimental functions of EVs in AD. Next, we discuss the role of
EVs in the pathogenesis of PD. Finally, we focus on how these EVs provide exciting opportunities to be
used as biomarkers in both diseases.
2. The Role of EVs in AD
2.1. The Convergence between the Generation of Aβ and EVs
Aβ is released by proteolytic processing of APP which can occur in a non-amyloidogenic or
amyloidogenic fashion [17–19]. The difference between both pathways can be attributed to the initial
cleavage step by either α-secretase or β-secretase, respectively. The former cleavage occurs within the
Aβ domain and thereby prevents the formation of a full-length Aβ peptide. Subsequently, the large
N-terminal ectodomain, called soluble APP α (sAPPα), is released, whereas the α-C-terminal fragment
(α-CTF or C83) remains bound to the membrane. Alternatively, the cleavage by the β-secretase,
called β-site APP cleaving enzyme-1 (BACE1), results in the formation of sAPPβ and β-CTF that
consists of 99 amino acids (C99). The next cleavages occur within the transmembrane domain of
α-CTF or β-CTF and are mediated through the γ-secretase complex. This leads to the release of the
cytoplasmatic APP intracellular domain (AICD) and either P3 (Aβ17–40/42) in the non-amyloidogenic
pathway or a longer Aβ species (including but not limited to Aβ1–38/40/42) in the amyloidogenic
pathway [20]. The difference in length of the secreted Aβ peptide is attributed to the different positions
where the sequential γ-secretase cleavages can occur, with Aβ1–40 being the most prevalent product that
is generated. However, in ~10% of the cases, Aβ1–42 is formed, which is considered to be more directly
related to AD pathology since it is more hydrophobic, aggregation prone and the major constituent of
amyloid plaques [12,21].
Both APP and the secretases traffic through multiple cellular compartments and co-localize at
several locations, although the exact processes are not completely unraveled. However, the following
routes leading to non-amyloidogenic processing at the plasma membrane and amyloidogenic
processing in intracellular compartments are generally proposed [18,19,22,23] (Figure 1). After its
synthesis in the endoplasmic reticulum (ER), APP is transported through the Golgi compartment
to the plasma membrane, where it is rapidly cleaved by α-secretase or re-internalized in
endosomes. Alternatively, APP can directly be transported from the trans-Golgi network (TGN)
to endosomes. These endosomes can recycle to the plasma membrane, undergo retrograde transport
to the TGN or mature into late endosomes which can fuse with lysosomes for degradation.
Additionally, the endosomes provide an acidic environment which is known to be ideal for BACE1
activity, hence leading to the amyloidogenic processing of APP. The active γ-secretase complex
is thought to be principally localized to the plasma membrane and in the endosomal/lysosomal
compartments, complementing the activity of α- and β-secretase, respectively, at these locations [18].
Little is known about how the intracellularly generated Aβ peptides are released into the extracellular
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compartment [23]. One option involves post-Golgi network transport pathways to the plasma
membrane, but also the secretion of Aβ via EVs has gained attention [23]. In this context, it is
interesting to know that late endosomes, which are also called multivesicular bodies (MVBs), can have
multiple destinations: they can either fuse with the lysosome, resulting in degradation, or they can
fuse with the plasma membrane, thereby releasing their intraluminal vesicles (ILVs) as EVs into the
extracellular environment [15].
Several studies suggest detrimental effects of altering the trafficking of APP in AD pathogenesis
with a central role for MVBs. Experiments in several APP-expressing cell lines and primary cortical
neurons indicate that the sorting of APP to ILVs in a subset of MVBs occurs via the endosomal sorting
complexes required for transport (ESCRT) pathway [24,25] and is dependent on the ubiquitination of
APP [24]. Furthermore, the trafficking of APP into EVs has also been reported to be dependent on
an Alix-Syntenin-1 pathway, independent of the ESCRT machinery [26]. In general, MVBs formed
by the ESCRT-dependent pathway are destined for lysosomal degradation [15]. Indeed, the direct
(i.e., via Hrs and Tsg101, both key players in the ESCRT pathway) and indirect (i.e., via Vps34, the main
source of phosphatidylinositol-3-phosphate (PI3P)—see below) inhibition of the ESCRT pathway
results in accumulation of APP in enlarged endosomes [24], whereas it reduces the lysosomal delivery
of APP, leading to intracellular Aβ accumulation [25]. The reported resulting effect on secreted
Aβ-levels is contradictory, namely increased [24] or decreased [25,27,28]. Interestingly, the levels
of PI3P are decreased in affected brain regions of late-onset AD patients and several transgenic
mice models of AD [24]. One of the functions of PI3P is its involvement in the recruitment of
ESCRT complexes that mediate the intraluminal sorting of ubiquitinated cargo proteins in MVBs.
Therefore, it can be speculated that reduced PI3P levels cause a decreased degradation of APP and
its metabolites in lysosomes, leading to intracellular Aβ accumulation and/or EV secretion as an
alternative cellular route for the MVBs. Furthermore, the intracellular Aβ accumulation might be
enhanced due to an increased residence time of APP in endosomal compartments which harbor
favorable conditions for amyloidogenic processing. In line with these hypotheses, PI3P depletion
in primary mouse cortical neurons results in the intracellular accumulation of APP-CTFs due to
decreased lysosomal degradation [28]. This is associated with a sphingolipid-dependent release of
APP-CTF-containing EVs, which is suggested by the authors to be a way of disposing of undigested
material [28]. Similarly, compromising the function of the lysosome in H4 glioblastoma cells expressing
a pathogenic PS1 mutation significantly increases both the release of EVs and the concentration of Aβ
associated with EVs [29].
The presence of several products of the APP metabolism in MVBs and EVs is reported by other
studies as well. APP and APP-CTFs have been detected in MVBs in cultured human cerebrovascular
cells [30] and in cortical neurons of APP751SL/PS1M146L mice [31], respectively. In APP-expressing
neuroblastoma SH-SY5Y cells, both APP itself, APP-CTFs and AICD are present in MVBs and on
secreted EVs that were isolated from the culture medium [32]. In neuroblastoma N2a cells expressing the
Swedish mutant form of APP (APPSwe), a minor fraction of the Aβ peptides present in MVBs is released
in association with EVs [33]. Another study showed that EVs isolated from these APPSwe-expressing
neuroblastoma N2a cells contain APP, α-CTF, β-CTF and Aβ1–40/42. In contrast, β-CTF and Aβ1–40/42
were respectively absent and lowered in EVs isolated from APPWT-expressing cells, whereas no
difference in the total amount of secreted EVs was detected [34]. Strikingly, the APP and/or CTFs
inside the EVs could be processed by γ-secretase of recipient cells, signifying that EVs can indeed
act as vehicles for the intercellular transport of APP and its metabolites [34]. APP and β-CTF were
detected in EVs secreted by APPSwe-expressing HEK293 and neuroblastoma SH-SY5Y cells as well [26].
Additionally, in vivo experiments show that EVs isolated from the hippocampus of AAV-C99-expressing
mice are enriched in α-CTFs and β-CTFs compared to controls. This is even more pronounced upon
treatment with a γ-secretase inhibitor, which also leads to the presence of higher molecular weight CTF
species inside the EVs [35]. Furthermore, EVs isolated from brain lysates of Tg2576 mice were shown
to contain APP, APP-CTFs and Aβ. The levels of APP and APP-CTFs inside these EVs are higher
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compared to the levels in EVs isolated from non-transgenic littermates. The APP-CTFs are enriched in
EVs compared to cell lysates, but no differences in the total amount of EVs were reported [36].
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Figure 1. The role of multivesicular bodies ( VBs) and extracellular vesicles (EVs) in a yloid precursor
protein (APP) processing. APP is synthesized in the endoplasmic reticulum (ER) and subsequently
transported through the Golgi compartment to early endosomes (1) or the plasma membrane (2), where it
can be cleaved by α-secretase in the non-amyloidogenic pathway. This cleavage leads to the formation
of soluble APP α (sAPPα) and the α-C-terminal fragment (α-CTF or C83). Alternatively, APP can
be re-internalized in endosomes (3) where the amyloidogenic cleavage by β-secretase preferentially
occurs. Thereby, sAPPβ and β-CTF (C99) are generated. The formation of the APP intracellular domain
(AICD) and either the P3 fragment or the amyloid β (Aβ) peptide from α- and β-CTF, respectively,
requires cleavage by the γ-secretase complex. Early endosomes recycle to the plasma membrane (4),
undergo retrograde transport to the trans-Golgi network (5) or mature into late endosomes/MVBs (6).
The latter either fuse with lysosomes (7) or with the plasma membrane (8), resulting in the extracellular
release of their intraluminal vesicles (ILVs) as EVs. Several products of the APP processing pathway
have been localized to MVBs (i.e., APP itself; α- and β- CTF; AICD; Aβ) and EVs (i.e., APP itself; α- and
β- CTF; Aβ; α-, β- and components of the γ-secretase complex), whereby Aβ can be localized both on
the inside and on the surface of EVs. Figure created with BioRender.
Cells 2020, 9, 2485 5 of 33
MVBs also appear to play an important role in the final cleavage step of the APP proteolysis
pathway that leads to the release of Aβ peptides. This cleavage is mediated by the γ-secretase
complex which consists of four subunits including presenilin (PS1 or PS2, encoded by PSEN1 and
PSEN2). It has been shown that depending on the PS subunit, the subcellular localization of the
γ-secretase complex differs [37]. If the γ-secretase complex contains PS2, it localizes specifically to late
endosomes/MVBs and lysosomes whereas, in the case of PS1, it is more broadly distributed throughout
the cell, including the plasma membrane. Strikingly, the γ-secretase cleavage in late endosomes/MVBs
and lysosomes generates an intracellular pool of longer Aβ species. Familial AD (FAD) mutations in
PSEN2 increase the intracellular Aβ1–42/Aβ1–40 ratio even more dramatically. Moreover, FAD mutations
in PSEN1 change its subcellular localization towards that of PS2, similarly promoting the generation
of intracellular Aβ1–42 species [37]. Interestingly, even prior to the formation of amyloid plaques,
Aβ1–42 was shown to accumulate in intraneuronal MVBs of Tg2576 mice and this accumulation
increased which age [38]. This suggests that intracellular Aβ accumulation is a very early event
in the pathogenesis of AD. Other studies reported the presence of Aβ in intraneuronal MVBs in
Tg2576 mice, both in vivo [25,38] and in vitro [39,40], in APPxPS1 mice [31] and in the human AD
brain [38,41]. Moreover, the aggregation of Aβ peptides has been shown to occur in acidic cellular
compartments, including late endosomes, inside neurons [42,43]. This indicates that MVBs are
important cellular compartments for both the generation, aggregation and accumulation of Aβ
peptides. Additionally, intracellular Aβ accumulation inside MVBs has been shown to affect the
MVB sorting pathway as well [40]. Although the sequence and the interplay between the described
events remain elusive, they suggest a feedback loop between aberrant subcellular trafficking of APP,
intracellular Aβ accumulation and a dysfunction in the endolysosomal–autophagic system, the latter
known to be an early pathological feature of AD [44]. Importantly, MVBs appear to be a central
intracellular compartment at the intersection of these events, harboring Aβ and other products of the
APP metabolism and providing a secretory mechanism for these components under the form of EVs.
Interestingly, BACE1, a disintegrin and metalloprotease 10 (ADAM10) and nicastrin, a component
of the γ-secretase complex, were shown to be present in EVs isolated from brain lysates of Tg2576
mice, indicating that the metabolic processing of APP could also occur here [36]. The latter was
confirmed in a later study, where it was shown that APP present in brain-derived EVs isolated from
Tg2576 mice and incubated in vitro in the absence of cells is cleaved to generate APP-CTFs and
AICD [45]. Similarly, EVs isolated from APP-expressing Chinese hamster ovary (CHO) cells contain
APP, APP-CTFs, Aβ and the secretases BACE, ADAM10, PS1 and PS2, although nicastrin could not be
detected in this study [46]. Altogether, it is clear that EVs are linked with the Aβ-generating pathway
that plays a central role in the pathogenesis of AD. In the next part of this review, we will discuss both
the beneficial and detrimental roles that have been attributed to EVs in AD.
2.2. The Beneficial Roles of EVs in AD
In wild-type (WT) rats, synaptic disruption caused by the intracerebroventricular (icv) infusion
of Aβ-containing human AD brain extracts was abrogated by EVs derived from N2a neuroblastoma
cells or cerebrospinal fluid (CSF) from healthy donors. This protective effect was obtained when the
EVs were either pre-infused or pre-incubated with the extracts and is likely due to the sequestration
of Aβ assemblies on the surface of the EVs [47]. Along these lines, another study reported that
N2a-derived EVs promote Aβ amyloidogenesis of both synthetic and endogenous Aβ, resulting in the
formation of Aβ assemblies associated with EVs which can be more efficiently taken up and degraded
by microglia in vitro [48]. According to the authors, the rationale behind this is that EVs accelerate
the formation of non-toxic amyloid fibrils, thereby resulting in a decline of the formation of toxic
oligomeric species [48]. Similarly, EVs derived from N2a cells [49] and astrocytes [50] were shown to
catalyse the aggregation of Aβ in vitro [49,50] and in vivo [50]. However, in these reports, this resulted
in a reduced uptake by N2a cells [49], accompanied by a reduced toxicity, and primary mixed glial
cultures [50]. This might be explained by the notion that Aβ fibrils are less efficiently taken up by
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target cells than AβO [51], whereby intracellular Aβ can have pathological consequences and appears
to play an important role in AD pathogenesis [52,53]. However, as a consequence, this might implicate
a role for EVs in the formation of extracellular Aβ plaques. Mechanistically, the interaction between
Aβ and the surface of the EVs was shown to be mediated by glycosphingolipids [48,54–56] and the
cellular prion protein (PrPC) [49] present on the EV membrane. Furthermore, it was shown that the
hippocampal administration of EVs isolated from N2a cells [54] or mouse primary neurons [55] in
APPSweInd mice causes a reduction in total Aβ levels and the amount of thioflavin-S positive plaques,
which was attributed to an EV-associated Aβ uptake by microglia [54]. It is, however, important to
note that the administered EVs are derived from healthy sources and that to acquire these positive
effects, normally functioning microglia need to be present. The same research group reported that
an oral treatment with plant-derived ceramides in APPSweInd mice increases the amount of serum
and brain tissue-derived EVs that are positive for Aβ and the neuronal markers neural cell adhesion
molecule 1 (NCAM-1) and L1 cell adhesion molecule (L1CAM). This suggests that the treatment
increases neuronal EVs harboring Aβ for clearance in vivo. Accordingly, the treatment reduced Aβ
pathology and inflammation in the brain, whereas cognitive function as assessed by the Y-maze test
was improved [56]. An alternative mechanism of EV-associated clearance of Aβ was reported in a study
where an increased degradation of Aβ by microglial cultures upon statin treatment was attributed to the
statin-induced release of insulin-degrading enzyme (IDE)-associated EVs [57]. Similarly, altering the
release of IDE-containing EVs in APPSwe-expressing neuroblastoma N2a affects the degradation of
extracellular Aβ [58].
2.3. The Detrimental Roles of EVs in AD
Although some studies reported beneficial effects of EVs derived from healthy sources in the
pathogenesis of AD, their role might be completely different when they are secreted by cells affected
by the disease process. Initially, EVs could act as a helpful mechanism to remove accumulating toxic
material from an affected cell but, paradoxically, these EVs might subsequently exert detrimental effects.
In line with this, EVs were proposed to be a potential escape mechanism for cells to be able to cope with
excess amounts of intracellular Tau [59,60]. Some data suggest that EV-associated Aβ could be involved
in plaque formation. Indeed, the EV marker Flottilin-1 partially colocalized with Aβ1–42 in senile
plaques of Tg2576 mice [61], whereas both Alix and Flotillin-1 are enriched in amyloid plaques of AD
patients compared to age-matched controls [33,62]. Additionally, Tau- and Aβ-containing EVs derived
from a variety of in vitro and in vivo sources were shown to be taken up by recipient cells in vitro and
in vivo, highlighting their potential as vehicles to spread AD-related proteins. In this context, both Tau
and AβO-containing EVs isolated from, respectively, the brain of PS19 Tauopathy mice [63] and AD
patients [41] were taken up by neuronal cultures. Subsequently, the AβO-containing EVs either release
their cargo, causing cytotoxicity, or migrate to further recipient cells [41]. The latter result was reported
in other studies and for Tau as well [64,65], supporting the notion that at least part of the EVs that are
taken up by the target cell can be re-secreted, thereby achieving a longer distance of action. To this
end, the internalized EVs were shown to hijack the secretory endosomal pathway in the recipient
neurons [65]. Interestingly, blocking the EV production, secretion or uptake in neuronal cultures reduces
the neuron-to-neuron spread of AβO and the related toxicity [41]. Furthermore, Aβ-containing EVs
isolated from PS1 mutant neurons and the CSF of sporadic, late-onset AD patients are neurotoxic
to primary rat cortical neurons, whereby there is a highly significant correlation between the EV
Aβ1–42 levels and the induced neurotoxicity [29]. In line with this, the in vitro neuronal toxicity of
human CSF-derived EVs (defined to be microvesicles) from AD patients is significantly decreased by
pre-treatment with anti-Aβ antibodies [66]. Astrocyte-derived EVs (ADEs) isolated from plasma of
AD patients exert a similar neurotoxicity in primary rat cortical neurons [67]. This was shown to be
due to high levels of several complement proteins in these ADEs that mediate the deposition of the
membrane attack complex on the neurons, causing their membrane disruption and the activation of
necroptosis [67,68]. Furthermore, the addition of microglia-derived EVs (defined to be microvesicles)
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to Aβ1–42 aggregates in vitro promoted the formation of small soluble neurotoxic Aβ1–42 species,
thereby increasing neurotoxicity in cultured primary hippocampal neurons [66].
Tau-containing EVs isolated from the culture medium of either Tau-stimulated microglia [63] or
Tau-transduced, human-derived induced pluripotent stem cells (iPSCs) [69] transfer their Tau content to
hippocampal neurons after their injection into the hippocampus of WT mice. Intriguingly, besides being
taken up and transferring their content, Tau-containing EVs have the potential to mediate the
propagation of Tau pathology. Indeed, EVs isolated from in vitro (i.e., N2a cells expressing
aggregation-prone Tau [64]) and in vivo (i.e., brain of Tau transgenic rTg4510 mice [70], CSF derived
from AD patients [64,71]) sources can induce Tau aggregation in in vitro systems optimized to assess
Tau seeding capacity. Moreover, hippocampal injection of EVs derived from rTg4510 brain induces
Tau phosphorylation at the site of injection in Tau transgenic ALZ17 mice [72]. Similar injection setups
in WT mice using EVs isolated from either FAD patient-derived [73] or Tau-transduced [74] neuronally
differentiated iPSCs revealed the same results. Furthermore, neuron-derived, phosphorylated
Tau (p-Tau)-containing EVs from AD and mild cognitive impairment (MCI) patients, but not
cognitively normal controls, can propagate Tau pathology upon their injection into the brain
of WT mice [75]. Functional studies showing beneficial effects of inhibiting EV secretion add
additional weight to the hypothesis that EVs play a detrimental role in the AD disease process.
Indeed, pharmacologically inhibiting EV synthesis by the systemic administration of GW4869,
an inhibitor of neutral sphingomyelinase 2 (nSMase 2), slows Tau propagation in a mouse model of rapid
Tau propagation [63] and reduces the plaque load in 5xFAD mice [50]. Moreover, genetically nSMase
2-deficient 5XFAD mice display a reduction in both plaque burden and Tau phosphorylation, whereas
cognitive function is improved [76]. Depleting microglia or microglial Bin1 reduces the EV-associated
Tau content in vivo and in vitro and supresses the propagation of Tau pathology in Tauopathy mouse
models as well [63,71].
Altogether, these data clearly point towards a detrimental role for EVs in the pathogenesis
of AD. However, it is important to add that only a minor part of extracellular Aβ (<1%) and Tau
(<0.2% to ~2–3%) is associated with EVs [33,64,77]. In line with this, the total levels of Aβ1–40/42 in
EVs isolated from plasma and CSF samples from AD patients were shown to be drastically lower
compared to the EV-free fraction of the respective sample types [29]. Nevertheless, the Aβ1–42/Aβ1–40
ratio was significantly higher in these EVs, underlining their importance in AD pathogenesis [29].
Additionally, Tau phosphorylated at Threonine 181 (pT181) [78] and oligomeric Tau [64] were suggested
to be enriched in human CSF-EVs compared to total CSF in, respectively, mild AD patients and both
AD patients and controls. Moreover, EV-associated Tau could induce Tau aggregation in vitro [64] and
Tau transduction in vivo [63], whereas naked Tau was unable to achieve these effects. Similar findings
were reported for EV-associated Aβ since EVs isolated from PS1 mutant neurons induce neurotoxicity
in primary rat cortical neurons to the same extent as EV-depleted medium, although the latter contains
about 10-fold more Aβ1–42 compared to the EVs [29].
3. The Role of EVs in PD
Next to AD, EVs have also been implicated in the pathogenesis of PD which is characterized
by the misfolding and aggregation of α-syn followed by its deposition in Lewy bodies and Lewy
neurites. Because α-syn lacks an ER targeting sequence, it was originally considered as an exclusively
intracellular protein. However, this concept was challenged by initial reports showing the presence
of extracellular α-syn in human CSF [79,80] and plasma [80,81]. Interestingly, studies in human
α-syn-expressing SH-SY5Y neuroblastoma cells indicated that α-syn is continuously secreted via
an ER/Golgi-independent mechanism involving the endocytic pathway, whereby at least part of
the secreted α-syn is associated with EVs [82–84]. Furthermore, it has been shown that α-syn can
interact with the ESCRT pathway, which ultimately can result in its release in association with
EVs [85,86]. Several studies collectively indicate that α-syn monomers, oligomers and fibrils can be
located both in the lumen and on the surface of EVs [82,83,87–92]. However, similar to what has
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been described for Aβ and Tau, only a minor component of the extracellular α-syn associates with
EVs [87,89,90,93–96]. Nonetheless, several observations point towards an important role for this
fraction in the pathogenesis of PD. Intravesicular α-syn, present in human α-syn-expressing SH-SY5Y
neuroblastoma cells, was shown to be more prone to aggregation compared to cytosolic α-syn [82].
EVs can also accelerate the aggregation of α-syn in vitro, whereby EVs derived from control N2a cells
exert the same effect as EVs derived from α-syn-overexpressing N2a cells [89]. Of specific relevance,
it was reported that EVs isolated from the CSF of patients with PD and dementia with Lewy bodies
(DLB), but not control patients, induce α-syn aggregation in vitro as well [95]. The addition of EVs
isolated from WT mouse brain induces the assembly of recombinant α-syn preformed fibrils (PFFs) into
higher-order multimers in vitro. In the same timeframe, no multimerization of α-syn PFF in the absence
of EVs was observed [97]. However, similarly to what was described for Aβ [47], the pre-incubation of
α-syn PFFs with these EVs neutralized the detrimental effects ofα-syn PFFs in vitro (i.e., reduced uptake
by primary cortical cultures) and in vivo (i.e., inability to induce α-syn accumulation after intrastriatal
injection in WT mice) [97]. Interestingly, the A53T α-syn mutant displays an increased association
with EVs, leading to the speculation that pathogenic α-syn species may be preferentially sorted into
EVs [90]. In line with this, misfolded and oligomeric α-syn (i.e., presumably the more toxic form of
α-syn) were shown to be favorably released with EVs compared to, respectively, native and highly
aggregated α-syn [84,98].
After their secretion,α-syn-containing EVs can be taken up by recipient neurons in vitro, where they
induce toxicity [87,99]. Of interest, the uptake of EV-associated oligomeric α-syn species derived from
α-syn-expressing H4 neuroglioma [87,94] and SH-SY5Y neuroblastoma [90] cells by the respective
naive cells is more efficient compared to that of EV-free α-syn. In line with this, sonication of EVs
derived from α-syn-overexpressing cell lines reduces their internalization and the transfer of α-syn
to recipient cells, indicating that the EVs need to be intact to efficiently exert these functions [87,88].
A functional study investigating the effect of nSMase 2 inhibition in SH-SY5Y cells further underlined
the role of EVs in the spreading of α-syn between neuronal cells. Indeed, nSMase 2 inhibition results
in reduced EV secretion in response to oligomeric α-syn. This is accompanied by a reduced transfer of
oligomeric α-syn to recipient cells [100]. Additionally, in vivo data show that the intrastriatal injection
of EVs isolated from human α-syn-expressing HEK cells in WT mice resulted in the spreading of the
human α-syn towards interconnected brain regions [99]. Similarly, α-syn neuronal inclusions were
detected close to the injection site upon the intracortical administration of CSF-derived EVs from
DLB patients in WT mice [92]. Strikingly, the uptake and transfer of α-syn-containing EVs has been
linked to the prion-like spreading of α-syn. EVs obtained from α-syn PFFs stimulated primary cortical
neurons act as seeds to induce endogenous α-syn aggregation in recipient neurons in vitro [101].
Additionally, brain-derived EVs from DLB patients facilitate α-syn aggregation in vivo after their
intracerebral injection in WT mice [102]. Similar results were seen after the intrastriatal injection
of plasma-derived EVs from PD patients [103]. Furthermore, α-syn-containing EVs derived from
serum of PD patients trigger α-syn aggregation, dopaminergic degeneration and motor deficits when
administered into the striatum of WT mice [104]. However, EVs isolated from A53T α-syn transgenic
mouse brain were unable to induce α-syn pathology and motor deficits after their intrastriatal injection
in WT mice [97].
Although all data described above focus on neuronal-derived EVs, there also appears to be a
role for microglia-derived EVs in PD pathogenesis. EVs derived from the plasma of PD patients
are internalized by microglia in vitro and in vivo, thereby inducing microglial activation in both
setups. Subsequently, BV-2 microglia were shown to secrete α-syn-containing EVs which induce
α-syn aggregation in SH-SY5Y recipient cells [103]. The stimulation of BV-2 microglia cells with
α-syn results in the release of EVs that are able to induce apoptosis in recipient neurons [105].
Additionally, α-syn PFF-stimulated primary microglia secrete α-syn oligomer-containing EVs which
trigger α-syn aggregation in vitro (i.e., in primary cortical neurons) and in vivo (i.e., upon intrastriatal
injection in WT mice), leading to the loss of dopaminergic neurons and the occurrence of motor deficits
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in the latter situation [101]. Interestingly, microglia/macrophage-derived CD11b positive EVs are
present in the CSF of PD and multiple system atrophy (MSA) patients and are able to induce α-syn
aggregation in vitro [101]. Together, these data underline the potential of microglia in facilitating the
propagation of α-syn via EVs.
Several PD-related assets can be linked with EV secretion. Environmental toxins, including certain
pesticides and metals, are hypothesized to play a role in the initiation and progression of PD pathology.
For example, chronic exposure to high doses of the neurotoxic metal manganese results in manganism
which is characterized by many Parkinsonian features [106]. Interestingly, manganese enhances the
release of α-syn oligomer-containing EVs from α-syn-expressing mouse dopaminergic neuronal cells.
When these EVs are injected into the striatum of WT mice, they propagate α-syn pathology and induce
the development of Parkinsonian motor deficits [107]. Additionally, exposure to the pesticide rotenone
is associated with developing PD [108]. In this context, it was shown that rotenone is able to induce
the release of α-syn in association with EVs from WT primary neurons [91]. Collectively, these studies
indicate a potential role for α-syn-containing EVs connecting environmental triggers and PD.
Furthermore, another molecule implicated in PD pathogenesis, namely the lipid peroxidation product
4-hydroxynonenal (HNE), induces the aggregation of endogenous α-syn in primary cortical neurons
as well as the release of α-syn oligomer-containing EVs [99]. An increasing body of evidence links a
dysfunction in the endolysosomal–autophagic system, which is increasingly recognized as a central
event in the pathophysiology of PD, to EV secretion too [109–111]. Indeed, blocking the fusion of the
autophagosome (AP) with the lysosome by Bafilomycin A1 (Baf) treatment in α-syn-overexpressing
neuronal cell lines increases vesicular α-syn release [84,87,88,92,98]. This is associated with a higher
transmission of α-syn to recipient SH-SY5Y cells [88]. Mechanistically, the Baf treatment results in the
accumulation of fused AP-MVB compartments in α-syn-overexpressing H4 cells, whereby the EVs
secreted by these cells contain several AP markers [92]. Furthermore, blocking autophagy by silencing
of autophagy-related gene 5 (ATG5) in α-syn-overexpressing Lund human mesencephalic (LUHMES)
neuronal cells protects them against the α-syn-induced toxicity by increasing the α-syn secretion in EVs.
As such, the EVs provide a compensatory rescue mechanism for impaired intracellular autophagy [112].
Another association between lysosomal dysfunction and PD is provided by the significant relevance of
the lysosomal enzyme glucocerebrosidase (GCase) in PD. Up to 7% of PD patients carry a mutation in
the GBA1 gene [113], whereas PD patients that do not carry a GBA1 mutation also show a significant
reduction in lysosomal GCase activity [114,115]. Interestingly, the pharmacological inhibition of GCase
by conduritol-B epoxide (CBE) in A53T α-syn transgenic mice significantly increases brain EV levels
and EV-associated oligomeric α-syn [116]. A Drosophila model of GCase deficiency shows markedly
increased EV numbers in the hemolymph (i.e., the Drosophila equivalent of blood) [117]. Moreover, it is
suggested that the excessive EV secretion caused by the GCase deficiency might be responsible for the
characteristic presence of protein aggregates in this model, since knocking down components of the
ESCRT pathway reduces the accumulation of these protein aggregates [117]. Strikingly, the ratio of EV
α-syn to total α-syn in plasma of PD patients is inversely correlated with GCase enzymatic activity,
which again suggests that GCase activity might be linked to the release of EVs [118].
4. EVs as Potential Biomarkers for AD and PD
AD and PD pathology begins multiple years before symptoms arise, hence the diagnosis
is made when considerable and irreversible neuronal damage has already occurred [119,120].
Therefore, it is of great importance to identify patients in the earliest stages of the disease, when potential
disease-modifying treatments might have the greatest benefit. To this end, biomarkers are of specific
interest. Next to diagnosing and monitoring disease, they could be instrumental in evaluating the
patients’ response to disease-modifying treatments. Interestingly, several studies already indicated
that EV-associated proteins might provide a snapshot of the molecular events occurring in the
brain of patients with neurodegenerative diseases and thereby serve as a liquid brain biopsy.
For example, an analysis of brain tissue-derived EVs revealed that Aβ and p-Tau are present in
Cells 2020, 9, 2485 10 of 33
EVs isolated from AD and DLB patients, whereas in the latter condition they contain α-syn as well [102].
Furthermore, EVs isolated from the temporal neocortex of AD patients contain significantly more
AβO compared to EVs from non-neurological control samples [41]. These results indicate that the
EV cargo can reflect brain pathology. Another study demonstrating a significant positive correlation
between the elevated levels of Tau phosphorylated at Serine 396 (pS396) and Aβ1–42 in brain tissue
homogenate and brain-derived EVs of AD patients supports this notion [121]. EV-bound Aβ derived
from plasma of AD patients was shown to strongly correlate with brain plaque deposition as assessed
by positron emission tomography (PET), whereas this was not the case for total plasma Aβ [122].
These results further demonstrate that brain biomarkers can be detected in the periphery as well.
Similarly, several miRNAs were shown to be upregulated in both brain tissue and serum-derived EVs of
AD patients, although there was little overall correlation between miRNA expression profiles in brain
homogenate, brain tissue-derived EVs and serum-derived EVs [123]. However, the authors suggest
that enriching for specific cell type-derived EVs from serum might improve this. Indeed, EVs that
are separated from plasma or serum based on their expression of the neuronal surface marker
L1CAM are enriched for neuronal proteins compared to the total EV population and control EV
subpopulations [124]. Alternatively, NCAM can also be used to enrich for neural-derived EVs (NDEs).
Using the latter method, it was shown that the levels of total Tau (t-Tau), pT181 Tau and Aβ1–42 in
plasma NDEs highly correlate with their respective levels in the CSF [125]. This further underlines the
potential of NDEs to reflect pathological changes in the brain [125]. A proteomics analysis of brain
tissue-derived EVs revealed that half of the quantified proteins displayed neuron-specific markers
and the other half glia-specific markers, whereby the former are enriched in the control group and
the latter in the AD group [121]. Another study reported the presence of several central nervous
system (CNS) cell type markers (i.e., neurons, microglia, oligodendrocytes and astrocytes) on human
brain tissue-derived vesicles that could be explored to capture specific cell type-derived EVs in the
periphery [126]. In summary, both the total population and specific cell type enriched EVs in a variety
of sources have emerged as potential biomarkers due to their role in the disease process and their
ability to carry disease-related molecules.
4.1. EVs as Biomarkers in AD
Although the majority of studies investigating EV-related biomarkers in AD have been focusing
on blood as an easily accessible biofluid, some results were reported in CSF. Both EVs derived from
CSF of AD patients and controls have been shown to contain Tau species that are phosphorylated
at several sites (i.e., pS262/pS356, pS396/pS404, pT181) [64,78]. The amount of p-Tau in CSF-EVs
did not differ between those two groups in one study [64], whereas another report described an
increase in the ratio of EV p-Tau to CSF t-Tau specifically in early AD patients [78]. The number of
isolectin B4 (IB4) positive particles (defined as myeloid microvesicles) is increased in the CSF of AD
patients and MCI patients converting to AD in comparison with stable MCI patients and controls [127].
These levels are associated with hippocampal atrophy and white matter tract damage in AD and MCI
patients, respectively [127]. A proteomics analysis on EV separated from CSF samples of AD patients,
MCI patients and corresponding controls identified the heat shock 70 kDa protein 1A (HSPA1A),
puromycin-sensitive aminopeptidase (NPEPPS) and prostaglandin F2 receptor negative regulator
(PTGFRN) as differentially expressed proteins, whereby HSPA1A and NPEPPS are significantly
increased in AD patients versus MCI patients and PTGFRN is significantly increased in AD patients
versus controls [128]. Additionally, a variety of biomarker candidates have been identified in plasma-
or serum-derived NDEs of AD patients. Several of these biomarkers have promising abilities to
distinguish patients from controls, whereby some of them might aid disease staging and even predict
disease development from a preclinical stage. These results are summarized in Table 1. As an indication
of the diagnostic ability of the identified biomarkers, the area under the receiver operating curve (ROC)
is included when available. Alternatively, the sensitivity, specificity or p-value are mentioned.
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Table 1. Overview of extracellular vesicle (EV)-associated biomarkers in Alzheimer’s disease (AD).
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This table only discusses results obtained in Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI) and controls (ctrl). Follow-up (FU) AD patients
provided samples at two time-points: first when cognitively intact and later when diagnosed with AD. ADC patients are MCI patients who are converting to AD. For reference [135],
cohort 1 consists of longitudinal samples collected from AD patients prior to symptom onset and respective controls, whereas cohort 2 consists of longitudinal samples of clinical
AD patients and respective controls. In the extracellular vesicle (EV) markers column, the + symbol indicates the assessment of typical EV markers whereas the—symbol indicates
the assessment of non-EV markers. For statistics, preferably the area under the receiver operating curve (AUC) or alternatively the sensitivity (sens) and specificity (spec) or p-value
are indicated. Preclinical biomarkers have the potential to identify patients at an early disease stage before the occurrence of clinical symptoms. Prognostic biomarkers have the
potential to differentiate between different stages of AD and follow-up disease progression. Abbreviations: QC, quality control; NTA, nanoparticle tracking analysis; TEM: transmission
electron microscopy; CSF, cerebrospinal fluid; p-Tau, phosphorylated Tau; t-Tau, total Tau; SNAP25, synaptosomal-associated-protein 25; Aβ, amyloid beta; REST, repressor element
1-silencing transcription factor; IRS-1, insulin receptor substrate-1; GAP43, growth-associated protein 43; LAMP-1, lysosome-associated membrane protein 1; HSP70, heat-shock protein 70;
LRP6, lipoprotein receptor-related protein 6; HSF1, heat-shock factor-1; AMPA4, GluA4-containing glutamate; NLGN1, neuroligin 1; NRXN2, neurexin 2a; NPTX2, neuronal pentraxin 2;
BACE1, β-site APP cleaving enzyme-1; sAPPα, soluble APPα; sAPPβ, soluble APPβ; IL-6, interleukin 6; TNF-α, tumor necrosis factor α; IL-1β, interleukin 1 β; TCC, terminal complement
complex; CR1, complement receptor type 1; DAF, decay-accelerating factor; HGF, hepatocyte growth factor; FGF, fibroblast growth factor; IGF1, insulin-like growth factor 1; L1CAM, L1 cell
adhesion molecule; NCAM, neural cell adhesion molecule; GLAST, glutamine aspartate transporter; CSPG4, chondroitin sulfate proteoglycan 4; PDGFRα, platelet growth factor receptor α;
ADE, astrocyte-derived EV; NDE, neural-derived EV.
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NDEs derived from plasma or serum from AD patients contain increased levels of pT181 Tau,
pS396 Tau and Aβ1–42 compared to controls [75,125,134,143]. Strikingly, this is already the case
for up to ten years before their diagnosis when these patients were still cognitively normal [134].
Moreover, the levels of those three markers are increased in MCI patients converting to AD in
comparison with stable MCI patients as well [75]. Therefore, this set of biomarkers has the potential
to distinguish different stages of AD whereby both persons at risk at their preclinical stage and MCI
patients that are most likely to progress to AD can be identified. Additionally, the plasma NDE levels
of pT181 Tau and Aβ1–42 highly correlate with their levels in the CSF, further underlining the potential
of NDEs to reflect pathological changes in the brain [125]. A large case–control study analyzed several
of these biomarker candidates in NDEs separated from longitudinal plasma samples collected prior
to AD disease onset which occurred on average four years after collecting the earliest preclinical
sample. NDEs from future AD patients contained longitudinally elevated mean levels of pT181 Tau and
pT231 Tau in comparison with controls, whereas t-Tau and, surprisingly, Aβ1–42 remained unaltered.
Furthermore, the NDE diameter was increased but no differences in NDE concentration could be
observed. Combining several repeated measures in a prediction model could predict AD with high
specificity [135]. Another study did not report differences between the pT181 Tau levels in NDEs from
patients with AD, MCI and controls [136]. The plasma NDE levels of pT181 Tau and Aβ1–42 in AD
patients also do not correlate with cognitive decline [138], whereas the mean longitudinal plasma
NDE levels of pT181 Tau in preclinical AD patients were associated with cognitive performance [135].
Total Tau levels in plasma-derived NDEs were shown to be indifferent between AD patients and
controls, but significantly upregulated in PD patients where they correlate with disease severity [142].
In contrast, increased levels of t-Tau have also been reported in plasma-derived NDEs from AD
patients [125]. Differences in the methods to enrich for NDEs and to assess the t-Tau levels might
provide an explanation for these discrepancies. Next to Aβ, other products of the APP processing
pathway (i.e., sAPPα and sAPPβ) are also increased in plasma NDEs from AD patients compared to
controls [143]. Serum-derived NDEs isolated from older individuals with age-related cognitive decline
milder than MCI or dementia also show higher pT231 Tau, pT181 Tau and t-Tau in comparison with
age-matched cognitively stable individuals [148].
Alterations in insulin signaling, such as dysregulated phosphorylation of the insulin receptor
substrate-1 (IRS-1), which can trigger insulin resistance, have been linked to the pathogenesis
of AD [137,149]. This is reflected in plasma-derived NDEs of AD patients since the levels of
IRS-1-pS312 and IRS-1-pTyr are increased and decreased, respectively, compared to controls [137].
Moreover, these altered levels correlate with brain atrophy in the AD patients, again supporting
that peripheral EV biomarkers can reflect changes in the AD brain [150]. Furthermore, the insulin
resistance index (i.e., the ratio of IRS-1-pS312 to IRS-1-pTyr) is significantly increased in the AD
condition. Strikingly, these differences already plateaued in preclinical patients up to ten years
before their AD diagnosis was made [137]. In line with these data, the mean IRS-1-pS312 levels
amongst longitudinal plasma-derived NDEs of preclinical AD patients were significantly elevated in
comparison with controls and were associated with worse cognitive performance. However, in this
sample set, the IRS-1-pTyr levels were significantly increased in preclinical AD patients as well [135].
Importantly, the levels of several insulin signaling mediators in serum-derived NDEs were shown
to be associated with a longitudinal, prospective change in cognitive performance in a cohort of
individuals with and without age-related cognitive decline [148]. The plasma NDE levels of several
synaptic proteins and transcription factors mediating neuronal protection are significantly decreased in
multiple AD stages (preclinical AD patients, MCI patients converting to AD, AD patients) compared to
controls and stable MCI patients [75,138–141]. In contrast, the levels of multiple lysosomal proteins are
significantly increased in the preclinical AD group compared to controls [139]. At the stage of diagnosis
one to ten years later, the levels of almost all synaptic proteins declined even further, whereas they
remained constant for most lysosomal proteins and the transcription factors [138–141]. The detailed
information of all investigated biomarkers of each category can be found in Table 1. These data suggest
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the identification of multiple promising preclinical biomarker candidates, whereas several synaptic
proteins additionally hold promise as prognostic biomarkers. Furthermore, the altered levels of several
biomarkers in NDEs correlate with the Mini Mental State Examination (MMSE) score of AD patients,
suggesting that they could be used to follow the progression of cognitive decline. This is the case for the
synaptosomal-associated-protein 25 (SNAP25) in serum NDEs and the synaptic proteins synaptopodin,
synaptophysin, GluA4-containing glutamate (AMPA4) and neuroligin 1 (NLGN1) in plasma-derived
NDEs, of which the levels are decreased in AD patients compared to controls [133,138,141]. A similar
positive correlation with the MMSE score was shown for the decreased levels of miR-223 in EVs isolated
from serum of dementia patients, including both AD and vascular dementia cases [130]. Since plasma
and serum-derived EVs have been shown to be enriched in miRNAs compared to cell-free plasma and
serum, the miRNA profile of EVs has also attracted considerable attention as a potential biomarker [151].
The levels of miR-193b are lower in EVs derived from serum of AD patients compared to MCI patients,
which in turn show decreased levels compared to controls [129,132]. Conversely, miR-384 show
the inverse pattern, whereas miR-135a is equally increased in MCI and AD patients [132]. Both in
serum- [131] and plasma- [145] derived EVs of AD patients, panels of differentially expressed miRNAs
were identified that could differentiate AD patients from controls. In plasma NDEs, miR-212 and
miR-132 are decreased in AD patients compared to controls [146]. Furthermore, decreased miR-100-3p
levels and increased miR-23a-3p, miR-223-3p and miR-190a-5p levels were reported in plasma NDEs
of AD patients in comparison with controls [147].
Next to NDEs, ADEs, isolated using an antibody against the glutamine aspartate transporter
(GLAST), have also been investigated. It has been shown that the total number of plasma
ADEs is significantly lower than the number of plasma NDEs in AD patients and controls.
Nonetheless, the plasma ADEs contain significantly higher levels of a number of proteins
(i.e., BACE1, γ-secretase, sAPPα, sAPPβ, pT181, pS396 and Aβ1–42) compared to NDEs [143]. From this
set of proteins, the levels of BACE1 and sAPPα are significantly higher, whereas the levels of Aβ1–42 and
the neural protein septin-8 are significantly lower in ADEs of AD patients compared to controls [143].
As a side note, the authors mention that these significant but moderate differences might be less useful to
diagnose AD. However, they might provide a way to monitor the effect of, for example, drugs that aim
to inhibit BACE1 [143]. Furthermore, a variety of complement proteins are significantly upregulated in
plasma ADEs of AD patients at the dementia stage, but not yet in the preclinical AD phase. In contrast,
the levels of the complement regulatory proteins CD59 and decay-accelerating factor (DAF) are already
decreased at the preclinical phase and further decline as the disease progresses [68]. Since complement
regulatory proteins normally prevent excessive complement activation, their decrease in the preclinical
phase might be the cause of complement activation in astrocytes later on [68]. Another subtype of
specific EVs that has been isolated are EVs derived from chondroitin sulfate proteoglycan (CSPG)
4 type neural precursor cells [144]. These EVs are less abundant in comparison with ADEs and NDEs in
plasma of AD patients and controls, but they contain significantly higher levels of several neurotrophic
factors whereby the levels are lower in both preclinical and later stage AD patients compared to
controls [144]. However, because of the low abundance of CSPG4 EVs, their biomarker potential will
likely be quite limited [144].
Interestingly, EVs have already been used for treatment follow-up in clinical trials. One trial
demonstrated improved cognition after a daily subcutaneous treatment with growth hormone-releasing
hormone (GHRH) over 20 weeks in MCI patients [152]. Plasma NDEs derived from those patients
contain significantly higher levels of Aβ1–42 and significantly lower levels of several synaptic
proteins (i.e., neurogranin, synaptophysin, synaptotagmin, synaptopodin) compared to controls.
However, the levels of none of these biomarkers were significantly altered due to the GHRH
treatment [153]. In the Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF120) clinical
trial, AD and MCI patients that were treated daily with an intranasal dose of 20 international units
(IU) of insulin for four months showed improved cognition [154]. This outcome correlates positively
with changes in IRS-1-pS312 and IRS-1-pTyr in plasma NDEs of these patients, although no significant
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difference in the levels of these markers between baseline and the study endpoint were detected. In the
future, these results could be helpful to determine which patients are most likely to benefit from the
treatment [155].
4.2. EVs as Biomarkers in PD
In PD patients, the total level of EVs was reported to be unchanged [156] or lowered [157] in
serum, unchanged in plasma [118] and increased in CSF [95]. Next to EV levels, a growing number
of studies found several promising candidate biomarkers associated with these EVs in a variety of
biological sources. These results are summarized in Table 2. In CSF samples, the α-syn EV levels are
lower in early stage PD patients compared to healthy controls. In contrast, no differences could be
detected in more advanced stage PD patients compared to neurological controls (i.e., polyneuropathy
and progressive supranuclear palsy (PSP) patients). However, compared to the latter three groups,
EVs derived from CSF of DLB patients show decreased levels of α-syn which correlate with the patients’
severity of cognitive impairment as assessed by the MMSE scores [95]. Another study specifically
investigated the microglia/macrophage-derived, CD11b positive EVs in CSF samples of PD, MSA and
control patients. Although the total number of EVs and the fibrillary α-syn levels do not differ, both the
total and oligomeric α-syn levels are increased in PD and MSA patients [101]. In plasma, the α-syn
levels in both the total pool [103,118] and the L1CAM positive [158,159] pool of EVs are significantly
elevated in PD patients compared to controls. More specifically, one study reported that the total,
monomeric and oligomeric α-syn levels in these plasma EVs are increased, whereas no differences
were detected in fibrillar α-syn [103]. Similarly, serum EVs isolated from PD patients were shown to
contain elevated levels of total, monomeric, oligomeric and pSer129 α-syn [104]. Of note, these EVs
also contain higher levels of the inflammatory cytokines tumor necrosis factor alpha (TNF-α) and
interleukin 1 beta (IL-1β) [104]. Furthermore, total α-syn levels in L1CAM positive serum EVs are
elevated approximately two-fold in conditions with Lewy body pathology compared to MSA and
unrelated neurodegenerative diseases [160]. As an important readout to monitor and predict disease
progression, it was shown that α-syn in plasma L1CAM positive EVs correlates with disease severity as
assessed by the Unified Parkinson’s Disease Rating Scale (UPDRS) score [158]. However, another report
did not identify this association [159]. Additionally, no correlation between α-syn in serum-derived,
L1CAM positive EVs and the UPDRS or Montreal cognitive assessment (MoCa) score was found [160].
In the total EV pool in plasma of PD patients, a negative correlation was found between the ratio of EV
α-syn to plasma α-syn and disease severity, as assessed by the Hoehn and Yahr (H&Y) score [118].
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Table 2. Overview of extracellular vesicle (EV)-associated biomarkers in Parkinson’s disease (PD).
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This table only discusses results obtained in Parkinson’s disease (PD) patients and controls (ctrl). In the extracellular vesicle (EV) markers column, the + symbol indicates the
assessment of typical EV markers whereas the—symbol indicates the assessment of non-EV markers. For statistics, preferably the area under the receiver operating curve (AUC) or
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ATP5A, adenosine triphosphate 5A; NDUFS3, NADH:ubiquinone oxidoreductase subunit S3; SDHB, succinate dehydrogenase complex iron sulfur subunit B; LRKK2, leucine-rich repeat
kinase 2; SNAP23, synaptosomal-associated protein 23.
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Next to α-syn, other EV-related proteins that could also serve as biomarker candidates were
identified. DJ-1 is significantly elevated in EVs isolated from plasma of PD patients compared
to controls [159]. Additionally, certain miRNAs are more (i.e., miR-24 and miR-195) or less
(i.e., miR-19b) abundant in serum EVs of PD patients [166]. In plasma-derived EVs of PD patients,
miR-331-5p is increased, whereas miR-505 is decreased [162]. Several mitochondrial markers
(i.e., ATP5A, NDUFS3 and SDHB) are decreased in serum EVs of PD patients as well [157,165].
More generally, a Raman spectroscopy analysis revealed that the molecular fingerprint of EVs isolated
from the serum of PD patients is different compared to controls. Therefore, this technique might
hold promise for the diagnosis and monitoring of PD once further optimized and validated [163].
Proteomics analyses from serum-isolated EVs revealed that several proteins are differentially abundant
between PD patients and controls [156,161,164]. For example, EVs from the plasma of PD patients
contain less clusterin, complement C1r and apolipoprotein A1 (ApoA-1) compared to controls [161].
Of particular interest, certain proteins are significantly altered between different PD stages as well,
underlining their potential as biomarkers to trace the progression of PD [161,164]. For example,
ApoA-1 is significantly lower in plasma EVs of H&Y stage III compared to stage II PD patients [161].
Additionally, in serum-derived EVs, a proteomics approach identified seven proteins that are
progressively upregulated from mild to severe PD, whereas seven other proteins progressively
decreased [164]. These progressively upregulated proteins include clusterin and complement C1r,
which contradicts the results that were obtained in plasma-derived EVs [161,164]. Next to potential
prognostic biomarkers, some promising results suggesting the use of EV biomarkers to distinguish
PD from other disorders were reported. In CSF, both EV-associated α-syn and the ratio of EV
α-syn to the total number of EVs could discriminate between PD, dementia with Lewy bodies and
neurological controls (i.e., polyneuropathy and progressive supranuclear palsy patients) with relatively
high sensitivity and specificity [95]. Furthermore, the combination of α-syn and clusterin in serum
NDEs allows us to discriminate between PD and both MSA (AUC: 0.91) and other proteinopathies
(i.e., frontotemporal dementia, corticobasal syndrome and PSP) (AUC: 0.98) [160].
Not only are CSF and plasma useful sources of potential EV-associated biomarker candidates, since
interesting results were obtained in the easily accessible biofluids saliva and urine as well. The number
of EVs in saliva from PD patients is increased compared to controls [173]. Additionally, saliva-derived
EVs from PD patients contain higher levels of oligomeric α-syn, whereas the ratio of total α-syn to
oligomeric α-syn is also increased compared to controls [172]. However, no association with disease
severity was found [172]. In urinary EVs, SNAP23 and calbindin are elevated in PD patients compared
to controls [171]. Similar results were obtained for DJ-1, although this only holds true for samples
derived from males [168]. In contrast, no differences in leucine-rich repeat kinase 2 (LRRK2) were
present [168], which was reported in other studies as well [167,169]. Mutations in LRKK2, which can
be phosphorylated at multiple sites, are one of the most commonly known genetic causes of PD [174].
Interestingly, the ratio of Ser(P)-1292 LRRK2 to total LRKK2 is increased in urinary EVs of PD patients
with and without LRKK2 mutations, whereby the Ser(P)-1292 LRRK2 levels in the latter group correlate
with several non-motor aspects of PD [169,170].
One study already reported the use of EVs for treatment follow-up in a clinical trial, namely the
Exenatide-PD trial. In this trial, the treatment group demonstrated a slight improvement in their
UPDRS motor score, whereas the control group continued to worsen [175]. Concomitantly, the levels
of IRS-1-pTyr increased in serum-derived NDEs from the Exenatide group compared to the
placebo group, suggesting an increase in brain insulin signaling pathways due to the treatment.
Additionally, an increase in downstream effector molecules (i.e., total and phosphorylated mechanistic
target of rapamycin (mTOR)) in these serum NDEs could be correlated with the improved UPDRS
motor score in the treatment group [176]. These data support the usability of EVs as tools to validate a
treatment response.
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5. Conclusions
CSF is the only biofluid that is currently included in the guidelines for the biomarker-based
definition of AD provided by the research framework of the National Institute on Aging–Alzheimer’s
Association (NIA-AAA) and the International Working Group (IWG) [177,178]. The CSF biomarker
profile defining AD consists of a low CSF Aβ1–42 or Aβ1–42/Aβ1-40 ratio, elevated CSF p-Tau and
elevated CSF t-Tau [177,178]. This CSF biomarker profile is not standardly used in clinical practice
but can increase diagnostic accuracy when the clinical diagnosis is inconclusive [179]. For PD,
no validated biomarker profile is available yet. PD diagnosis is based on clinical symptoms as
described in the International Parkinson and Movement Disorder Society Clinical Diagnostic Criteria
for PD [180]. Therefore, there is a great need for novel and additional biomarkers with the ability
to predict, diagnose and follow-up disease. Preferentially, these biomarkers should be derived
from easily accessible biofluids. Although the collection of CSF via a lumbar puncture is a safe
procedure [181], it still remains rather invasive. However, the alternative use of blood-based candidate
biomarkers implicates several challenges. Blood is a complex fluid in which potential biomarkers
are susceptible to potential proteolytic degradation and in which they are generally present at a low
concentration [182,183]. The usability of α-syn as a reliable biomarker in blood is further complicated
because the majority of α-syn that is present in blood derives from red blood cells [184]. EVs can
overcome some of these challenges and therefore provide a highly interesting alternative biomarker
source. Because of their ability to cross the brain barriers [185], they can be detected in peripheral
biofluids in which they protect their cargo from degradation. Furthermore, the biomarker of interest
is often enriched in EVs in comparison with the total biofluid. This can improve the measurement
sensitivity, lower the detection threshold and enhance the signal-to-noise ratio. The use of specific
markers to enrich for EVs derived from cellular sources that are known to be involved in the disease
process even further improves these advantages [124]. Nonetheless, the use of EVs as biomarkers also
comes with several considerations. A variety of isolation methods are currently available to separate
EVs from biological fluids, as is reflected in Tables 1 and 2. Each method has its own specificity and
efficiency, thereby influencing the identification of EV cargo [186]. Quality control measures are of
utmost importance to verify the depletion of contaminants and the successful separation of EVs from a
given biofluid [16]. Additionally, pre-analytical variables in collecting (e.g., timepoint of sampling),
processing (e.g., centrifugation speed) and storing (e.g., temperature) samples prior to the EV isolation
can influence the obtained results [187,188]. Punctiliously reporting all experimental parameters and
quality control measurements as proposed by the transparent reporting and centralizing knowledge
in EV research (EV-TRACK) initiative and the minimal information for studies of EVs (MISEV)
guidelines is therefore indispensable for reproducible and reliable EV research [16,186]. Prior to the
potential implementation of EV assays in the clinic, fully validated and standardized protocols will be
needed [189]. Furthermore, the identified EV-related biomarker candidates will need to be validated
in large datasets to verify the initial results. Although there is still a long way to go, EV biomarker
research is an exciting field which holds great promise to be of value to patients in the future.
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